Result of General Meeting

RNS Number : 5876J

Synairgen plc

14 April 2020

 

Synairgen plc

('Synairgen' or the 'Company')

Result of General Meeting

Southampton, UK - 14 April 2020: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce the passing of the Resolutions at the General Meeting held earlier today. The Conditional Placing and Subscription remain conditional on Admission of the relevant New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Wednesday 15 April 2020.

As announced on 31 March 2020, the first patient was dosed in the Company's double-blind, placebo-controlled trialof SNG001 (the Company's wholly-owned inhaled formulation of interferon-beta-1a) in COVID-19 patients. The trial has now been labelled as an Urgent Public Health study by the National Institute for Health Research (NIHR).   F urther updates will be made in due course.  

With effect from Admission, the Company will have 149,433,442 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Following Admission, the shareholdings of the Directors of the Company are as follows:

Director	Ordinary Shares held prior to the Fundraising	New Ordinary Shares subscribed for in the Fundraising	Ordinary Shares held after the Fundraising	Percentage of the Enlarged Issued Share Capital held
Simon Shaw	1,474,096	57,143	1,531,239	1.02%
Dr Bruce Campbell	294,259	28,571	322,830	0.22%
Prof. Stephen Holgate	858,360	28,571	886,931	0.59%
Richard Marsden	310,682	57,143	367,825	0.25%
Dr Phillip Monk	230,314	14,286	244,600	0.16%
John Ward	339,006	28,571	367,577	0.25%
Iain Buchanan	112,741	-	112,741	0.08%

Capitalised terms in the text of this announcement have the meanings given to them in the Company's circular dated 27 March 2020.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen  

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. 

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

COVID-19

COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people and those with co-morbidities such as heart and lung complications or diabetes are at greatest risk of developing severe or fatal disease.

Interferon beta (IFN-beta) potential applicability to COVID-19

Interferon beta is a naturally occurring protein, which orchestrates the body's antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility of these at-risk patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2 and MERS-CoV, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells either prevents or greatly diminishes cell damage and viral replication, respectively. Synairgen's SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action.

Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. We have also shown that treatment with inhaled SNG001 reduced lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia. At the time of the MERS-CoV outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the US to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro.

COVID-19 Clinical Trial

Synairgen's Phase II trial in COVID-19 patients (SG016) is a double-blind, placebo-controlled trial. Initially, the pilot phase of the study will involve 100 COVID-19 patients, will take place across a number of NHS trusts and has been adopted by the NIHR Respiratory Translational Research Collaboration, which is comprised of leading centres in respiratory medicine in the UK whose internationally recognised experts are working together to accelerate development and discovery for COVID-19. A successful outcome from the pilot phase will inform onwards progression of SNG001 in COVID-19 patients.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Simon Shaw
2.	Reason for the Notification
a)	Position/status	PDMR - Non-executive Chairman
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 p each
	Identification code	GB00B0381Z20
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35 pence 57,143
d)	Aggregated information: · Aggregated volume · Price	N/A, single transaction as per 4c above
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Bruce Campbell
2.	Reason for the Notification
a)	Position/status	PDMR - Non-executive director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 p each
	Identification code	GB00B0381Z20
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35 pence 28,571
d)	Aggregated information: · Aggregated volume · Price	N/A, single transaction as per 4c above
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Prof. Stephen Holgate
2.	Reason for the Notification
a)	Position/status	PDMR - Non-executive director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 p each
	Identification code	GB00B0381Z20
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35 pence 28,571
d)	Aggregated information: · Aggregated volume · Price	N/A, single transaction as per 4c above
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Richard Marsden
2.	Reason for the Notification
a)	Position/status	PDMR - CEO
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 p each
	Identification code	GB00B0381Z20
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35 pence 57,143
d)	Aggregated information: · Aggregated volume · Price	N/A, single transaction as per 4c above
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr. Philip Monk
2.	Reason for the Notification
a)	Position/status	PDMR - Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 p each
	Identification code	GB00B0381Z20
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35 pence 14,286
d)	Aggregated information: · Aggregated volume · Price	N/A, single transaction as per 4c above
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Ward
2.	Reason for the Notification
a)	Position/status	PDMR - Finance Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 p each
	Identification code	GB00B0381Z20
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 35 pence 28,571
d)	Aggregated information: · Aggregated volume · Price	N/A, single transaction as per 4c above
e)	Date of the transaction	15 April 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

ROMEAELLFSPEEFA